Department of Chemistry, University of Modena & Reggio Emilia, Italy-Via Giuseppe Campi 183, 41100 Modena, Italy.
Bioorg Med Chem. 2010 Sep 15;18(18):6805-12. doi: 10.1016/j.bmc.2010.07.047. Epub 2010 Jul 29.
The DFG motif at the beginning of the activation loop of the MAPK p38alpha undergoes a local structural reorganization upon binding of allosteric type-II and type-III inhibitors, which causes the residue F169 to move from a buried conformation (defined as DFG-in) to a solvent exposed conformation (defined as DFG-out). Although both experimental and computer simulation studies had been performed with the aim of unveiling the details of the DFG-in to DFG-out transition, the molecular mechanism is still far from being unequivocally depicted. Here, the accelerated molecular dynamics (AMD) technique has been applied to model the active loop flexibility of p38alpha and sample special protein conformations which can be accessible only in some conditions or time periods. Starting from the assumption of an experimentally known initial and final state of the protein, the study allowed the description of the interaction network and the structural intermediates which lead the protein to change its loop conformation and active site accessibility. Besides a few important hydrogen bond interactions, a primary role seems to be played by cation-pi interactions, involving the DFG-loop residue F(169), which participate in the stabilization of an intermediate conformation and in its consequent transition to the DFG-out conformation. From this study, insights which may prove useful for inhibitor design and/or site directed mutagenesis studies are derived.
DFG 基序位于 MAPK p38α 的激活环的起始处,在结合变构 II 型和 III 型抑制剂时会发生局部结构重排,这导致残基 F169 从埋藏构象(定义为 DFG-in)移动到溶剂暴露构象(定义为 DFG-out)。尽管已经进行了实验和计算机模拟研究,旨在揭示 DFG-in 到 DFG-out 转变的细节,但分子机制仍远未被明确描绘。在这里,加速分子动力学(AMD)技术已被应用于模拟 p38α 的活性环灵活性,并采样仅在某些条件或时间段内可获得的特殊蛋白质构象。从蛋白质的实验已知初始和最终状态开始,该研究允许描述导致蛋白质改变其环构象和活性位点可及性的相互作用网络和结构中间体。除了一些重要的氢键相互作用外,似乎还涉及阳离子-π 相互作用,涉及 DFG 环残基 F(169),其参与稳定中间构象及其随后向 DFG-out 构象的转变。从这项研究中,得出了可能对抑制剂设计和/或定点突变研究有用的见解。